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Abstract 
Dioxane-type (9’-anthracenyl)methylene acetal of methyl 2,3-di-O-methyl--D-
glucopyranoside was cleaved with LiAlH4-AlCl3 (3:1) or with Na(CN)BH3-HCl 
regioselectively to provide the 4- or 6-O-(9’-anthracenyl)methyl ether, respectively. 
Hydrogenolytic reaction of the exo and endo isomers of dioxolane-type acetals proved to be 
directed by the configuration of the acetalic carbon as well as the intramolecular participation 
of the adjacent free hydroxyl; ring opening reaction of the endo isomer of the methyl 2,3-O-
(9’-anthracenyl)methylene-α-L-rhamnopyranoside took place with complete selectivity 
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resulting in the axial (9’-anthracenyl)methyl ether, whereas a 1:1 mixture of the axial and 
equatorial ethers was formed upon same reaction of the exo isomer. Catalytic hydrogenation 
of the sugar acetals resulted in (9’,10’-dihydro-9’-anthracenyl)methylene derivatives without 
affecting the acetalic center. High-temperature molecular dynamics simulations and DFT 
(Density Functional Theory) geometry optimizations were carried out to study the 
conformation of the dioxane-type (9’,10’-dihydro-9’-anthracenyl)methylene acetal. 
 
Keywords 9-Anthracenylmethylene acetal, Regioselective, Hydrogenolysis, High-
temperature MD, DFT 
 
Corresponding author. Tel.: +36 52512900/22462; fax: +36 52512900/22342. 
E-mail address: borbasa@puma.unideb.hu (A. Borbás). 
 
1. Introduction 
 
Regioselective transformation of polyhydroxy compounds, such as carbohydrates, 
necessitates the application of protective groups which can be attached or cleaved in a 
selective manner to obtain partially substituted molecules. Modification of simple sugars and 
synthesis of higher oligosaccharides can not be carried out without the use of these 
methodologies.1 
The acetal-type protecting groups possess significant advantages such as simultaneous 
protection of two hydroxyls, the easy removal and the possibility of a partial deprotection. By 
the adequate selection of the hydride donor and various protic or Lewis acid reagents as well 
as solvents, any of the two protected hydroxyls can be liberated regioselectively.2 
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Most recently the 9-anthraldehyde acetal as a new protecting group was proposed by 
Ellervik3 reporting the synthesis of (9’-anthracenyl)methylene acetals of the 2-
(trimethylsilyl)ethyl -D-glucopyranoside and the phenyl 1-thio--D-galactopyranoside in an 
acetal exchange reaction. The anthraldehyde acetals can be cleaved under reductive 
conditions with Na(CN)BH3 and HCl/Et2O in THF to give 6-O-(9’-anthracenyl)methyl ethers, 
and can be selectively removed in the presence of benzylidene acetals. Due to the good 
crystalline properties and strong absorbance and fluorescence the (9’-anthracenyl)methylene 
acetal and (9’-anthracenyl)methyl ether may become useful as new protecting groups. 
These results prompted us to investigate the regioselective ring opening reaction and 
deprotection procedures of dioxane- and dioxolane-type (9’-anthracenyl)methylene-acetals of 
sugars. 
 
2. Results and discussion 
2.1. Synthesis and reactivity of dioxane-type (9’-anthracenyl)methylene acetals 
 
To prepare the dioxane-type acetal 2, methyl α-D-glucopyranoside 1 was treated with 
anthraldehyde dimethyl acetal in the presence of (±)10-camphorsulfonic acid (CSA). The OH 
groups of position 2 and 3 were methylated to obtain the fully protected methyl 4,6-O-(9’-
anthracenyl)methylene-2,3-di-O-methyl--D-glucopyranoside 3 (Scheme 1).  
Upon treatment of compound 3 with LiAlH4-AlCl34 (3:1) the methyl 4-O-(9’-
anthracenyl)methyl-2,3-di-O-methyl--D-glucopyranoside 4 could be isolated in crystalline 
form in a yield of 70%. Transformation of 3 with Na(CN)BH3 and HCl/Et2O in dry THF5 
mainly resulted in methyl 6-O-(9’-anthracenyl)methyl-2,3-di-O-methyl--D-glucopyranoside 
5, and its regioisomer 4 was also formed as a minor product. 
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It has been known since 1936 that 4,6-O-benzylidene acetals of glucose can be 
catalytically reduced into the corresponding 4,6-diols.6 However, catalytic hydrogenation of 3 
surprisingly did not affect the acetalic center, but affected the antracenyl ring resulting in 
methyl 4,6-O-(9’,10’-dihydro-9’-anthracenyl)methylene-2,3-di-O-methyl--D-
glucopyranoside 6 which was stable under hydrogen atmosphere in the presence of Pd catalyst 
for as long as 5 days. The structure of compound 6 was determined on the basis of 1H- and 
13C-NMR spectroscopy and X-ray crystallography as well. Molecular modeling was also 
applied to investigate the conformation of the (9’,10’-dihydro-9’-anthracenyl)methylene 
moiety. 
In order to study the selective removal of the (9’-anthracenyl)methyl ether moiety in the 
presence of acetyl, benzoyl or p-methoxybenzyl (PMB) groups the free hydroxyl of 
compound 4 was substituted by a simple acetylation, benzoylation and p-methoxybenzylation 
to furnish compounds 7-9, respectively. All three fully protected derivatives 7-9 were treated 
with BF3OEt2 in dry CH2Cl2 at 0 °C. Selective cleavage of the (9’-anthracenyl)methyl group 
of 7 and 8 liberating the OH-4 took place in 20 minutes to afford compounds 107 and 11,8,9 
respectively. In the case of compound 9 not only the (9’-anthracenyl)methyl group but also 
the PMB group was cleaved under these conditions to give the diol 12.10 
Reductive ring opening reaction of the partially hydrogenated acetal derivative 6 was 
also studied. We assumed that the acetalic center of 4,6-O-acetal ring anchored to the 
aliphatic 9’-carbon is less reactive under hydrogenolytic conditions than that of compound 3 
anchored to an aromatic carbon. Compound 6 was treated with LiAlH4-AlCl3 (3:1) under the 
conditions applied for the conversion of 3 into 4, however no reaction could be observed. 
Interestingly, the reaction of 6 with Et3SiH in the presence of BF3OEt211 in dry CH2Cl2 
resulted in two products, 13 and 14. Unreacted starting material 6 also remained after 24 h. 
Compound 13 proved to be methyl 6-O-(9’,10’-dihydro-9’-anthracenyl)methyl-2,3-di-O-
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methyl--D-glucopyranoside. The byproduct 14 could be purified after acetylation (1415) 
and was identified as 1,5-anhydro-4-O-acetyl-6-O-(9’,10’-dihydro-9’-anthracenyl)methyl-2,3-
di-O-methyl-D-glucitol on the basis of NMR. This result has experimentally proved the high 
stability of this type of acetal 6 and the formation of 14 is assumed to take place via 
compound 13. Hydrogenolysis of the glycosidic acetal resulting in a glucitol derivative is 
extremely rare upon reductive cleavage of benzylidene type acetals,12 since glycosides are 
more stable than the aromatic acetals. 
 
 
Scheme 1. Reagents and conditions: (a) anthraldehyde dimethylacetal, cat. CSA, dry MeCN, 
rt, 3 h, 79%; (b) MeI, NaH, DMF, 0 °C, 3 h, 90%; (c) from 3: LiAlH4, AlCl3 (3:1), Et2O, 
CH2Cl2, rt, 4 h, 70%; (d) from 3: Na(CN)BH3 in THF, HCl/Et2O, rt, 5 min, 48% for 5, 12% 
for 4; (e) Pd(C), H2, EtOH, rt, 6 h, 90%; (f) Ac2O, pyridine, rt, 2 h, 80% for 7; (g) BzCl, 
pyridine, CH2Cl2, 0 °C, 2 h, 89% for 8; (h) PMBCl, NaH, DMF, 0 °C, 2 h, 82% for 9; (i) 
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BF3OEt2, CH2Cl2, 0 °C, 20 min, 75% for 10, 76% for 11, 79% for 12; (j) BF3OEt2, Et3SiH, 
CH2Cl2, 0 °C, overnight, 20% for 13; (k) Ac2O, pyridine, rt, 2 h, 14% for two steps. 
 
2.2. Synthesis and reactivity of dioxolane-type (9’-anthracenyl)methylene acetals 
 
The vicinal cis-axial/equatorial hydroxyl groups of pyranosides react with acetalating 
reagents to form dioxolane-type acetal derivatives. The corresponding anthraldehyde 
dimethylacetal have not been used as protecting group for vicinal diols so far. Methyl α-L-
rhamnopyranoside was considered to be an excellent model compound to study the synthesis 
and hydrogenolysis of dioxolane-type (9’-anthracenyl)methylene acetals. Treatment of methyl 
-L-rhamnopyranoside 16 with anthraldehyde dimethylacetal resulted in a 1:4.5 mixture of the 
17endo and 17exo isomers, in a moderate yield (55%). Since these isomers could not be 
completely separated by column chromatography, the mixture was acetylated, and the 
separation of the obtained mixture of 18endo and 18exo was successful. After deacetylation 
of 18endo and 18exo, respectively, the 17endo- and exo-acetals could be obtained in 
crystalline form (Scheme 2). 
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Scheme 2. Reagents and conditions: (a) anthraldehyde dimethylacetal, cat. CSA, dry MeCN, 
rt, 1 d, 46% for 17exo, 9% for 17endo. (b) Ac2O, pyridine, rt, 1 h; (c) NaOMe, MeOH, rt, 1 h. 
 
The determination of the absolute configuration of the dioxolane-type acetals is a rather 
complex task although the 1H-NMR spectra can help if both isomers are available. Since the 
late seventies the chemical shift values of acetalic protons and carbons have been applied for 
the structure elucidation of the dioxolane-type structures.13 The acetalic configuration of 
compounds 17 and 18 were proven by 1H-NMR spectroscopy; H-acetalic of 17- and 18endo 
isomers resonate at higher field ( 7.08 and 7.12 ppm) while H-acetalic signals of 17- and 
18exo isomers are at lower field ( 7.47 and 7.58 ppm). Resonance values of the acetalic 
carbons are the followings: 17endo: 102.2 ppm, 18endo: 101.8 ppm and 17exo:100.3 ppm, 
18exo:100.8 ppm. 
We studied ring-opening reaction of the dioxolane-type acetals 17endo and 17exo 
possessing an extremely bulky anthracenyl substituent at the acetalic center. It was earlier 
shown that the cleavage of the five-membered benzylidene-type acetal rings is directed by the 
stereochemistry of the acetalic center. Namely, upon exo arrangement of the bulky 
substituent, the reagent attacks the axial oxygen atom forming the axial hydroxyl and 
equatorial benzyl-ether derivatives, selectively. On the contrary, in the case of endo 
arrangement of the bulky group, the equatorial oxygen atom is attacked leading to the 
formation of the equatorial hydroxyl and axial ether type products, also with full selectivity. 
Recently a rule of thumb (x, x, x) was formulated for the ring opening reactions of the 
dioxolane acetals by the following way: exo isomer gives axial hydroxyl.14 In good agreement 
with our expectations the cleavage of 17endo with LiAlH4-AlCl3 (3:1) gave methyl 2-O-(9’-
anthracenyl)methyl--L-rhamnopyranoside 20, exclusively. Surprisingly, treatment of 17exo 
with LiAlH4-AlCl3 (3:1) resulted in a 1:1 mixture of the equatorial (9’-anthracenyl)methyl-
ACCEPTED MANUSCRIPT 
 9 
ether derivative 19 and the axial (9’-anthracenyl)methyl-ether derivative 20. The loss of 
selectivity in the ring opening reaction of the 17exo acetal is seemed to disagree with the rule 
of thumb. In fact, we supposed, that the rule is valid, and the formation of the axial hydroxyl 
derivative 19 is due to the directing effect of the bulky exo-substituent of the acetalic carbon. 
However, an opposite directing effect of the free OH-4 next to the acetal ring also appears and 
gives rise to the formation of the axial ether 20. We demonstrated earlier15,16 in the course of 
symmetrical acetals of sugars that an adjacent free hydroxyl could participate in the opening 
reaction of the acetal ring. Being a free hydroxyl present at the acetal derivative first the 
reagents reacted with the OH free forming an aluminate derivative, then the cleavage of the 
acetal occurred through an intramolecular complexation of the adjacent oxygen of the acetal 
ring. The formation of the axial ether derivative 20 upon hydrogenolysis of 17exo was 
assumed via this mechanism.  
In order to prove our assumption compound 17exo was benzylated, and the fully 
protected 21exo was subjected to reductive ring opening reaction using LiAlH4 and AlCl3 
(3:1) as the reagents. The reaction gave exclusively the equatorial (9’-anthracenyl)methyl-
ether derivative 22 as expected. In the course of hydrogenolytic cleavage, hydrolysis of the 
dioxolane acetals also occured decreasing the yields of compounds 19, 20 and 22. 
Catalytic hydrogenation of compound 17exo took place in a similar manner as observed 
in the case of compound 3; the acetalic center stayed intact and the 9’,10’-positions of the 
anthracenyl ring were saturated to afford compound 23exo (Scheme 3). 
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Scheme 3. Reagents and conditions: (a) LiAlH4, AlCl3 (3:1), Et2O, CH2Cl2, 0 °C, 2 h; (b) 
BnBr, NaH, dry DMF, 0 °C, 1 h, 92%; (c) Pd(C), H2, EtOH, rt, 8 h, 95%. 
 
The (9’,10’-dihydro-9’-anthracenyl)methylene acetals of sugars have not been known in 
the literature and this kind of structure could be interesting in a sterical point of view. 
Therefore, conformational studies of the presumed roof-like structure of the (9’,10’-dihydro-
9’-anthracenyl)methylene acetal ring of 6 was performed by means of computational and X-
ray crystallographic methods. 
 
2.3. Computational study of the 9,10-dihydro-9-anthraldehyde (24) and the (9’,10’-
dihydro-9’-anthracenyl)methylene acetal of glucopyranoside (6) and comparison to the 
X-ray experiment 
 
First, a simple aldehyde was chosen as a model compound for the computational 
studies. 100ns constant temperature molecular dynamics simulation has been carried out at 
1200K on the partially hydrogenated 9,10-dihydro-9-anthraldehyde 24 in order to explore the 
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low energy regions of the conformational energy (hyper) surface. 100 thousands geometries 
(snapshots) have been saved and each of them was minimized applying the GAFF empirical 
force field. Due to the relatively high temperature molecular dynamics simulations it can be 
plausibly assumed, that the low energy region of the conformational energy surface is 
sufficiently sampled, i.e. geometry optimization from the saved trajectory snapshots will find 
all the conformers corresponding to local energy minima which are non-negligibly populated. 
The geometries obtained this way constituted three distinct clusters of conformers. The 
geometry of a representative member of each cluster (with the lowest energy) was further 
optimized at the B3LYP/6-31G(d) level of theory. The computed energies and populations of 
the stable conformers of compound 24 are given in Table 1. As it is immediately apparent, the 
axial position of the aldehyde group is substantially more preferable than the equatorial one. 
In addition, while the axial position of the aldehyde group can exist in two (three, if the 
mirrored conformers are counted independently) stable conformations differing only in the 
relative orientation of the carbonyl oxygen, only one (two mirror related) conformer found 
with equatorial aldehyde group. It is especially interesting, that interchanging the aldehyde O 
and H atoms at the conformer 24c causes a conformational (equatorialaxial) transition to 
the most stable conformer 24a. 
 
 
Table 1. Computed empirical force field (GAFF) and zero point vibrational energy corrected density functional 
(B3LYP/6-31G(d)) energies and relative energies as well as the estimated percentage populations (based on the 
corrected density functional energies and the Boltzmann energy distribution) of conformers for compound 24. 
 
GAFF B3LYP/6-31G(d) Geometry 
 E (kJ/mol) ∆E (kJ/mol) E+ZPVE (a.u.) ∆E (kJ/mol) 
Percentage population 
(at 300K)(%) 
24a 44.354 0 -653.822281 0 70.98 
24b 56.223 11.869 -653.821431 2.232 29.01 
24c 69.973 25.619 -653.813038 24.267 0.01 
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The computational protocol detailed above was applied for the methyl 4,6-O-(9’,10’-
dihydro-9’-anthracenyl)methylene-2,3-di-O-methyl--D-glucopyranoside 6. It resulted in six 
structures which are schematically depicted and the corresponding numerical results are 
summarized in Table 2. Not surprisingly, the partially hydrogenated anthracenylmethylene 
group favors the equatorial position to the sugar ring. On the other hand, acetalic C became 
axial to C-9’ as it was expected, based on the conformational analysis of the model compound 
24.  
 
Table 2. Computed empirical force field (GAFF) and zero point vibrational energy corrected density functional 
(B3LYP/6-31G(d)) energies and relative energies as well as the estimated percentage populations (based on the 
corrected density functional energies and the Boltzmann energy distribution) of conformers for compound 6. 
 
GAFF B3LYP/6-31G(d) Geometry 
E (kJ/mol) ∆E (kJ/mol) E+ZPVE (a.u.) ∆E (kJ/mol) 
Percentage population 
(at 300K)(%) 
6a 245.396 0 -1382.220653 1.366 28.75 
6b 246.792 1.396 -1382.220375 2.095 21.46 
6c 252.835 7.439 -1382.221173 0 49.71 
6d 269.563 24.167 -1382.214537 17.423 0.05 
6e 274.761 29.365 -1382.214000 18.823 0.03 
6f 281.164 35.768 -1382.213114 21.159 0.01 
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The structure of methyl 4,6-O-(9’,10’-dihydro-9’-(R)-anthracenyl)methylene-α-D-
glucopyranoside determined by X-ray measurements (shown in Figure 1), corresponds 
perfectly to 6a, which is predicted as the most stable structure by GAFF empirical force field 
and showed one of the considerably populated one suggested by B3LYP/6-31G(d) method 
(Table 2). Figure 2 shows the correlation between X-ray geometry of 6 and DFT optimized 
geometry of 6a. 
 
Figure 1. Structure of compound 6 determined by single crystal X-ray diffraction together 
with partial numbering scheme. 
 
 
Figure 2. Correlation of X-ray structure of 6 and DFT optimized 6a structure. 
 
3. Conclusion 
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Dioxane- and dioxolane-type (9’-anthracenyl)methylene acetal of sugars could be 
readily prepared by means of acetal exchange reaction. Reductive hydrogenolysis of the (9’-
anthracenyl)methylene acetal ring showed the similar pattern of regioselectivity as observed 
in the case of benzylidene acetals. Reaction of methyl 4,6-O-(9’-anthracenyl)methylene-2,3-
di-O-methyl--D-glucopyranoside with LiAlH4-AlCl3 (3:1) or with Na(CN)BH3-HCl 
provided regioselectively the 4- or 6-O-(9’-anthracenyl)methyl ether, respectively. 
Hydrogenolytic reaction of the exo and endo isomers of dioxolane-type acetals with AlH3 was 
directed by the configuration of the acetalic carbon as well as the intramolecular participation 
of the adjacent free hydroxyl. Due to the joint effects the endo isomer of the methyl 2,3-O-
(9’-anthracenyl)methylene-α-L-rhamnopyranoside afforded the axial (9’-anthracenyl)methyl 
ether exclusively, whereas the exo isomer resulted in a 1:1 mixture of the axial and equatorial 
ethers upon ring opening reaction. The ring cleavage of the fully protected exo isomer (21exo) 
afforded the expected equatorial (9’-anthracenyl)methyl ether exclusively, in the lack of 
directing effect of an adjacent free hydroxyl. The (9’-anthracenyl)methyl group could be 
removed selectively with BF3OEt2 in the presence of acetyl or benzoyl groups. To remove 
the (9’-anthracenyl)methylene acetal catalytic hydrogenation proved to be inefficient, and 
resulted in the stable (9’,10’-dihydro-9’-anthracenyl)methylene derivatives without affecting 
the acetalic center. Catalytic hydrogenation of 9-anthraldehyde into 9-methyl-1,2,3,4,5,6,7,8-
octahydro-anthracene is known from the literature,17 the unexpected stability of the 9’,10’-
dihydro-9’-anthracenyl)methylene derivatives of sugars was explained by computational 
methods. 
The computational studies outlined above show that more than one local energy 
minimum with non-negligible population are exist which correspond to axial acetalic 
orientations and they are substantially more stable than the equatorial ones. It means that 
although the X-ray experiment shows the global minimum in solid phase, in solution the 
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existence of other axial conformation also might have contribution to the observed properties. 
Another consequence of the axial acetal conformation and the roof-type shape of the 
hydrogenated anthracenyl group is the loss of tight fit to the surface of catalysator and this 
way the loss of full hydrogenation. 
 
4. Experimental 
4.1. General Methods 
 
Optical rotations were measured at room temperature with a Perkin-Elmer 241 
automatic polarimeter. Melting points were determined on a Kofler hot-stage apparatus and 
are uncorrected. TLC was performed on Kieselgel 60 F254 (Merck) with detection by 5% 
sulfuric acid in ethanol. Column chromatography was performed on Silica Gel 60 (E. Merck 
0.062–0.200 nm). The organic solutions were dried over MgSO4 and concentrated in vacuum. 
The 1H (200.13, 360.13 and 500.13 MHz) and 13C NMR (50.3, 90.54, 125.76 MHz) spectra 
were recorded with Bruker WP-200SY, Bruker AM-360 and Bruker DRX-500 spectrometers 
for solutions in CDCl3. Internal references: TMS (0.00 ppm for 1H), CDCl3 (77.00 ppm for 
13C). MALDI-TOF MS spectra were recorded on a Bruker Biflex III spectrometer in positive, 
linear mode using saturated 2,4,6-trihydroxy-acetofenon in water as matrix. X-ray diffraction 
data was collected at 293 K, Enraf Nonius MACH3 diffractometer, Mo K radiation = 
0.71073 Å. The structure was solved by SIR-92 program18 and refined by full-matrix least-
squares method on F2, with all non-hydrogen atoms refined with anisotropic thermal 
parameters using the SHELXL-97 package19, publication material was prepared with the 
WINGX- suite.20 All hydrogen atoms were located geometrically and refined in the rigid 
mode. The molecular dynamics simulations and the preliminary geometry optimizations using 
the suitably developed GAFF empirical force field on the trajectory snapshot geometries were 
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carried out by means of the Amber molecular dynamics simulation package.21 B3LYP/6-
31G(d) density functional calculations were carried out using the Gaussian 03 package.22 At 
the B3LYP/6-31G(d) minima the zero point vibrational energy correction at the same level of  
theory also were computed. Ball-and-stick representations of the conformers were generated 
by the Molekel23 and VMD24 softwares. 
 
4.1.1. Methyl 4,6-O-(9’-anthracenyl)methylene--D-glucopyranoside (2) 
 
To a mixture of methyl -D-glucopyranoside 1 (3.0 g 15.4 mmol) and anthraldehyde 
dimethylacetal3 (4.56 g 18.1 mmol) in MeCN (20 mL) was added catalytic amount of (±)10-
camphorsulfonic acid (CSA) and was stirred at room temperature for 3 h. The mixture was 
neutralized by addition of Et3N and concentrated, then co-evaporated with toluene three 
times. The residue was crystallized from Et2O-hexane to give 2 (4.64 g, 79%) as white 
needles: mp 192-194 °C; []D +106 (c 0.14, CHCl3); 1H NMR (200 MHz, CDCl3): δ (ppm) 
8.59 (d, 2H, J 8.5 Hz), 8.46 (s, 1H), 7.97 (d, 2H, J 8.0 Hz), 7.58-7.37 (m, 4H), 6.80 (s, 1H, 
acetalic), 4.50 (d, 1H, J1,2 3.9 Hz, H-1), 4.33 (dd, 1H, J 10.4 Hz, J 4.7 Hz), 4.0 (dt, 1H, J 9.9 
Hz, J 4.7 Hz), 3.87 (dd, 1H, J 9.3 Hz, J 2.4 Hz), 3.82 (d, 1H, J 11.6 Hz), 3.7 (d, 1H, J 10.3 
Hz), 3.50-3.35 (m, 2H), 3.31 (s, 3H, OCH3), 2.73 (d, 1H, J 8.7 Hz, OH); 13C NMR: (50 MHz, 
CDCl3): δ (ppm) 131.5, 129.9, 129.6, 129.0, 126.6, 126.2, 124.8 (aromatic), 100.5 (C 
acetalic), 99.9 (C-1), 82.1 (C-4), 72.5, 71.3 (C-2, C-3), 69.9 (C-6), 62.3 (C-5), 55.6 (OCH3); 
Anal. Calcd. for C22H22O6 (382.41): C 69.10, H 5.80. Found: C 69.43, H 5.71. 
 
4.1.2. Methyl 4,6-O-(9’-anthracenyl)methylene-2,3-di-O-methyl--D-glucopyranoside (3) 
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Compound 2 (1.58 g, 4.36 mmol) was stirred in dry DMF (10 mL), treated with NaH 
(0.40 g, 60%, 3 equiv) at 0 °C. Methyl iodide (0.70 mL, 11.2 mmol, 2.71 equiv) was added 
dropwise and the reaction temperature was kept at 0 °C for 1 h. Then it was allowed to warm 
up to rt, and no starting material was indicated by TLC after 2 h. To the mixture MeOH was 
added to decompose the unreacted NaH and then it was concentrated, diluted with CH2Cl2, 
washed twice with water, dried (MgSO4) and concentrated. After column chromatography 
(6:4 hexane-EtOAc) compound 3 (1.52 g, 90%) was isolated as a syrup: []D +85 (c 0.16, 
CHCl3); 1H NMR (200 MHz, CDCl3): δ (ppm) 8.66 (d, 2H, J 8.7 Hz), 8.42 (s, 1H), 7.93 (dd, 
2H, J 8.4 Hz, J 0.8 Hz), 7.55-7.36 (m, 4H), 6.89 (s, 1H, acetalic), 4.89 (d, 1H, J 3.8 Hz, H-1), 
4.43 (dd, 1H, J 10.1 Hz, J 4.7 Hz), 4.26-4.11 (m, 1H), 4.09 (dd, 1H, J 14.3 Hz, J 7.2 Hz), 3.90 
(t, 1H, J 10.2 Hz), 3.80-3.72 (m, 1H), 3.52 (2s, 6H, 2 x OCH3), 3.41 (s, 3H, OCH3), 3.34 (dd, 
1H, J2,3 8.9 Hz, H-2); 13C NMR (50 MHz, CDCl3): δ (ppm) 131.4, 129.6, 129.6, 128.8, 126.9, 
125.9, 124.9, 124.7 (aromatic), 100.6 (C acetalic), 98.5 (C-1), 83.1, 81.4, 79.8 (C-2, C-3, C-
4), 69.9 (C-6), 62.3 (C-5), 60.8, 59.2 (2 x OCH3), 55.5 (anomeric OCH3). MALDI-TOF MS 
m/z calcd. for C24H26O6 : 410.17. Found: 410.42 [M]+ and 433.38 [M+Na]+. Anal. Calcd. for 
C24H26O6: C 70.23, H 6.38. Found: C 70.33, H 6.32. 
 
4.1.3. Methyl 4-O-(9’-anthracenyl)methyl-2,3-di-O-methyl--D-glucopyranoside (4) 
 
To a stirred suspension of the starting acetal 3 (2.1 g, 5.1 mmol) in dry CH2Cl2 and Et2O 
(30 mL, 2:1) LiAlH4 (0.86 g, 4.5 equiv) and solution of AlCl3 (1.0 g, 1.5 equiv) in Et2O (10 
mL) were added carefully under argon at 0 °C, then stirred for 4 h at rt. After complete 
conversion 2-3 mL of EtOAc and 1-5 drops of water were added, the mixture was diluted with 
EtOAc, washed 3 times with water, dried and concentrated. The crude syrup was crystallized 
from EtOH to give pale yellow crystalline product and mother liquor was purified by column 
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chromatography (7:3 hexane-acetone) to give 4 with 70% overall yield (1.46 g): mp 145-146 
°C; []D +112 (c 0.10, CHCl3); 1H NMR (500 MHz, CDCl3): δ (ppm) 8.47 (d, 2H, J 9.0 Hz, 
H-1’, H-8’), 8.44 (s, 1H, H-10’), 7.98 (d, 2H, J 8.5 Hz, H-4’, H-5’), 7.55-7.40 (m, 4H, H-2’, 
H-3’, H-6’, H-7’), 5.81 (d, 1H, J 11.0 Hz, ArCH2), 5.71 (d, 1H, J 11.0 Hz, ArCH2), 4.80 (d, 
1H, J1,2 3.6 Hz, H-1), 3.80 (s, 3H, OCH3), 3.75-3.60 (m, 4H), 3.55-3.50 (m, 1H), 3.53 (s, 3H, 
OCH3), 3.32 (s, 3H, OCH3), 3.29 (dd, 1H, J2,3 9.1 Hz, H-2), 1.80 (bs, 1H, OH); 13C NMR 
(125 MHz, CDCl3): δ (ppm) 131.4, 130.9, 129.0, 128.7, 128.5, 126.3, 124.9, 124.3 (aromatic), 
97.2 (C-1), 83.5, 82.8, 76.6 (C-2, C-3, C-4), 70.6 (C-5), 66.6 (ArCH2-), 61.7 (C-6), 61.3, 58.6 
(2 x OCH3), 55.0 (OCH3 anomeric); Anal. Calcd. for C24H28O6 (412.48): C 69.88, H 6.84. 
Found: C 69.96, H 6.75. 
 
4.1.4. Methyl 6-O-(9’-anthracenyl)methyl-2,3-di-O-methyl--D-glucopyranoside (5) and 
compound (4)  
 
To a stirred suspension of the starting acetal 3 (0.39 g, 0.96 mmol) and Na(CN)BH3 
(0.54 g, 9 equiv) in dry THF (5 mL) containing 3 Å MS was added HCl in Et2O dropwise 
until the evolution of gas ceased. After 5 min TLC showed complete conversion of the 
starting material. The mixture was diluted with CH2Cl2 (100 mL), washed with satd NaHCO3 
and water, then dried (MgSO4) and concentrated. After column chromatography (1:1 hexane-
EtOAc) compound 5 (227 mg, 48%) was isolated as a syrup: []D +63 (c 0.17, CHCl3); 1H 
NMR (360 MHz, CDCl3): δ (ppm) 8.39 (d, 3H), 7.95 (d, 2H, J 8.4 Hz), 7.47 (dt, 4H), 5.55 (d, 
1H, J 11.5 Hz, ArCH2), 5.47 (d, 1H, J 11.6 Hz, ArCH2), 4.84 (s, 1H, J1,2 3.4 Hz, H-1), 3.90-
3.75 (m, 2H), 3.68 (m, 1H, H-5), 3.60-3.33 (m, 12H, incl. 3x OCH3), 3.17 (dd, 1H, J2,3 9.1 
Hz, H-2); 13C NMR (90 MHz, CDCl3): δ (ppm) 130.9, 130.5, 128.5, 128.3, 127.9, 125.7, 
124.5, 124.0 (aromatic), 97.0 (C-1, JC1,H1 170 Hz), 82.5, 81.2, 70.2, 70.0 (C-2, C-3, C-4, C-5), 
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69.2 (ArCH2-), 65.3 (C-6), 60.5, 58.1 (2 x OCH3), 54.7 (OCH3 anomeric); Anal. Calcd. for 
C24H28O6 (412.48): C 69.88, H 6.84. Found: C 70.06, H 6.63.  
Compound 4 was also formed (56 mg, 12%). 
 
4.1.5. Methyl 4,6-O-(9’,10’-dihydro-9’-anthracenyl)methylene-2,3-di-O-methyl--D-
glucopyranoside (6) 
 
Compound 3 (0.45 g, 1.1 mmol) was dissolved in 96% EtOH (25 mL) and stirred under 
H2 atmosphere in the presence of 10% Pd/C (75 mg) for 6 h. The catalyst was removed by 
filtration through a layer of Celite, washed with EtOH, and the solvent was evaporated. The 
residue was crystallized from MeOH to give 6 (360 mg, 79%) as white needles: mp 172-174 
°C; []D +51 (c 0.19, CHCl3); 1H NMR (200 MHz, CDCl3): δ (ppm) 7.40-7.10 (m, 8H, 
aromatic), 4.72 (d, 1H, J1,2 3.7 Hz, H-1), 4.63 (d, 1H, J 5.2 Hz, H-acetalic), 4.22 (d, 1H, J 4.4 
Hz, H-9’), 4.17 (d, 1H, J 16.9 Hz, H-10’a), 3.99 (dd, 1H, J 10 Hz, J 4.6 Hz), 3.78 (d, 1H, J 
18.1 Hz, H-10’b), 3.60-3.40 (m, 8H, incl. 2 x OCH3), 3.33 (s, 3H, anomeric OCH3), 3.30 (t, 
1H, J 10.1 Hz), 3.14 (t, 1H, J 9.4 Hz), 3.12 (dd, 1H, J2,3 9.3 Hz, H-2); 13C NMR (50 MHz, 
CDCl3): δ (ppm) 137.3, 137.2, 135.1, 134.9, 130.0, 129.8, 127.4, 127.3, 126.7, 125.6 
(aromatic), 103.5 (C-acetalic), 98.3 (C-1), 81.8, 80.9, 79.8 (C-2, C-3, C-4), 68.6 (C-6), 61.9 
(C-5), 60.6, 59.3 (2 x OCH3), 55.0 (anomeric OCH3), 51.0 (C-9’), 35.8 (C-10’). MALDI-TOF 
MS m/z calcd. for C24H28O6 : 412.19. Found: 435.40 [M+Na]+. Anal. Calcd. for C24H28O6: C 
69.88, H 6.84. Found: C 70.03, H 6.69. 
 
4.1.6. Methyl 6-O-acetyl-4-O-(9’-anthracenyl)methyl-2,3-di-O-methyl--D-
glucopyranoside (7) 
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To a solution of 4 (250 mg, 0.61 mmol) in pyridine (2 mL) was added Ac2O (1 mL), 
and stirred for 2 hours. Then the reaction mixture was concentrated and co-evaporated twice 
with toluene. After column chromatography (7:3 hexane-EtOAc) compound 7 was isolated 
(220 mg, 80%) as a syrup: []D +144 (c 0.11, CHCl3); 1H NMR (500 MHz, CDCl3): δ (ppm) 
8.42 (d, 2H, J 9.0 Hz, H-1’, H-8’), 8.40 (s, 1H, H-10’), 7.96 (d, 2H, J 8.5 Hz, H-4’, H-5’), 
7.60-7.40 (m, 4H, H-2’, H-3’, H-6’, H-7’), 5.75 (d, 1H, J 11.5 Hz, ArCH2), 5.70 (d, 1H, J 
11.5 Hz, ArCH2), 4.80 (s, 1H, J1,2 3.5 Hz, H-1), 4.12-4.08 (m, 1H), 3.95 (dd, 1H, J 12.0 Hz, J 
3.5 Hz), 3.81 (s, 3H, OCH3), 3.75-3.60 (m, 3H), 3.59 (s, 3H, OCH3), 3.33 (s, 3H, OCH3), 
3.40-3.30 (dd, 1H, J 4.0 Hz), 1.77 (s, 3H, COCH3); 13C NMR (125 MHz, CDCl3): δ (ppm) 
170.3 (CO) 131.5, 131.0, 129.0, 128.6, 126.4, 125.0, 124.3 (aromatic), 97.2 (C-1), 83.9, 82.5, 
76.0, 68.4 (C-2, C-3, C-4, C-5), 66.3 (ArCH2), 62.9 (C-6) 61.5, 58.7 (2 x OCH3), 55.1 
(anomeric OCH3) 20.2 (OCOCH3); Anal. Calcd. for C26H30O7 (454.51): C 68.71, H 6.65. 
Found: C 68.52, H 6.77. 
 
4.1.7. Methyl 4-O-(9’-anthracenyl)methyl-6-O-benzoyl-2,3-di-O-methyl--D-
glucopyranoside (8) 
 
To a solution of 4 (123 mg, 0.30 mmol) in dry CH2Cl2 (2 mL) and dry pyridine (2 mL) 
was added BzCl (42 µL, 1.2 equiv) at 0 °C and the mixture was stirred for 2 h. Then the 
reaction mixture was diluted with CH2Cl2, washed twice with water, dried (MgSO4) and 
concentrated. After column chromatography (7:3 hexane-EtOAc) compound 8 (138 mg, 89%) 
was isolated as a syrup: []D +102 (c 0.12, CHCl3); 1H NMR (500 MHz, CDCl3): δ (ppm) 
8.43 (d, 2H, J 9.0 Hz, H-1’, H-8’), 8.26 (s, 1H, H-10’), 7.88 (d, 2H, J 8.5 Hz, H-4’, H-5’), 
7.82 (d, 2H, J 9.0 Hz,) 7.55-7.45 (m, 3H) 7.40-7.30 (m, 4H, H-2’, H-3’, H-6’, H-7’), 5.83 (d, 
1H, J 11.5 Hz, ArCH2), 5.76 (d, 1H, J 11.5 Hz, ArCH2), 4.82 (s, 1H, J1,2 3.5 Hz, H-1), 4.42 
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(dd, 1H, J 11.8 Hz, J 2.0 Hz), 4.23 (dd, 1H, J 12.0 Hz, J 3.5 Hz), 3.85 (s, 3H, OCH3), 3.85-
3.76 (m, 4H), 3.55 (s, 3H, OCH3), 3.36 (s, 4H, incl. OCH3); 13C NMR (125 MHz, CDCl3): δ 
(ppm) 165.8 (COPh) 132.9, 131.4, 131.0, 129.8, 129.5, 129.1, 128.7, 128.4, 126.4, 125.0, 
124.2 (aromatic), 97.2 (C-1), 84.0, 82.7, 76.3, 68.6 (C-2, C-3, C-4, C-5), 66.5 (ArCH2), 63.2 
(C-6) 61.5, 58.7 (2 x OCH3), 55.2 (anomeric OCH3); Anal. Calcd. for C31H32O7 (516.58): C 
72.08, H 6.24. Found: C 72.66, H 6.01. 
 
4.1.8. Methyl 4-O-(9’-anthracenyl)methyl-6-O-p-methoxybenzyl-2,3-di-O-methyl--D-
glucopyranoside (9) 
 
To a solution of 4 (127 mg, 0.31 mmol) in dry DMF (3 mL) was added NaH (20 mg, 
80%, 1.5 equiv) at 0 °C and the mixture was stirred for 20 min, then PMBCl (50 µL, 1.2 
equiv) was added and stirred for 4 h. Then the reaction mixture was diluted carefully with 
MeOH and concentrated. The residue was dissolved in CH2Cl2, washed twice with water, 
dried (MgSO4) and concentrated. After column chromatography (7:3 hexane-EtOAc) 
compound 9 (135 mg, 82%) was isolated as a syrup: []D +118 (c 0.09, CHCl3); 1H NMR 
(500 MHz, CDCl3): δ (ppm) 8.41 (s, 1H, H-10’), 8.41 (d, 2H, J 8.5 Hz, H-1’, H-8’), 7.97 (d, 
2H, J 8.0 Hz, H-4’, H-5’), 7.50-7.40 (m, 4H, H-2’, H-3’, H-6’, H-7’), 7.18 (d, 2H, J 8.5 Hz), 
6.81 (d, 2H, J 8.5 Hz), 5.77 (d, 1H, J 11.0 Hz, ArCH2), 5.66 (d, 1H, J 11.0 Hz, H- ArCH2), 
4.86 (s, 1H, J1,2 3.5 Hz, H-1), 4.30 (s, 2H, pCH3OPhCH2), 3.82 (t, 1H, J 8.0 Hz), 3.76-3.65 
(m, 9H, incl. 2 x OCH3) 3.65-3.60 (m, 4H, incl. OCH3), 3.39-3.35 (m, 4H, incl. OCH3); 13C 
NMR (125 MHz, CDCl3): δ (ppm) 159.2, 131.6, 131.0, 130.2, 129.2, 128.0, 126.2, 124.9, 
124.6, 113.8 (aromatic), 97.3 (C-1), 83.8, 82.7, 76.7, 70.1 (C-2, C-3, C-4, C-5), 73.0 
(pCH3OPhCH2), 66.5 (anthr-CH2), 66.6 (C-6), 61.5, 58.7 (2 x OCH3), 55.2, 55.1 
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(pCH3OPhCH2, anomeric OCH3); Anal. Calcd. for C32H36O7 (532.62): C 72.16, H 6.81. 
Found: C 72.32, H 6.71. 
 
4.1.9. Methyl 6-O-acetyl-2,3-di-O-methyl--D-glucopyranoside (10) 
 
To a solution of 7 (42 mg, 0.09 mmol) in dry CH2Cl2 (1 mL) at 0 °C was added 
BF3OEt2 (2 µL) and the mixture was stirred for 20 min. When TLC (4:6 hexane-EtOAc) 
showed complete conversion of the starting material (Rf 0.65) into the title compound (Rf 
0.22) 1 drop of Et3N was added and the solvent was evaporated. After column 
chromatography (3:7 hexane-EtOAc, Rf 0.27) compound 107 (18 mg, 75%) was isolated as a 
syrup: []D = +85 (c 1.28, CHCl3), lit.7 +85 (CH2Cl2); 1H NMR (360 MHz, CDCl3): δ (ppm) 
4.86 (d, 1H, J1,2 3.5 Hz, H-1), 4.45 (d, 1H, J6a,6b 12.1 Hz, J6a,5 4.8 Hz, H-6a), 4.27 (d, 1H, J6b,5 
2.1 Hz, H-6b), 3.80-3.70 (m, 1H, H-5), 3.65 (s, 3H, OCH3), 3.55-3.35 (m, 8H, 2 x OCH3, H-3, 
H-4), 3.25 (dd, 1H, J2,3 9.4 Hz, H-2), 2.77 (bs, 1H, 4-OH), 2.12 (s, 3H, OCOCH3); 13C NMR 
(90 MHz, CDCl3): δ (ppm) 97.5 (C-1), 82.5, 81.7 (C-2, C-3), 69.9, 69.3 (C-4, C-5), 63.2 (C-
6), 61.3, 58.6 (2 x OCH3), 55.3 (anomeric OCH3), 20.8 (OCOCH3); Anal. Calcd. for C11H20O7 
(264.27): C 49.99, H 7.63. Found: C 50.38, H 7.42. 
 
4.1.10. Methyl 6-O-benzoyl-2,3-di-O-methyl--D-glucopyranoside (11) 
 
To a solution of 8 (47 mg, 0.09 mmol) in dry CH2Cl2 (1 mL) at 0 °C was added 
BF3OEt2 (2 µL) and the mixture was stirred for 20 min. TLC (4:6 hexane-EtOAc) showed 
complete conversion of the starting material (Rf 0.72) into the title compound (Rf 0.32). Then 
1 drop of TEA was added and the solution was evaporated. After column chromatography 
(3:7 hexane-EtOAc, Rf 0.52) compound 118,9 (22 mg, 76%) was isolated as a syrup: []D +81 
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(c 0.11, CHCl3), lit.9 +75 (CH2Cl2); 1H NMR (360 MHz, CDCl3): δ (ppm) 8.06 (d, 2H, J 7.4 
Hz, o-H aromatic), 7.57 (t, 1H, J 7.4 Hz, p-H aromatic), 7.44 (t, 2H, J 7.7 Hz, m-H aromatic), 
4.87 (d, 1H, J1,2 3.5 Hz, H-1), 4.67 (d, 1H, J6a,6b 12.1 Hz, J6a,5 4.9 Hz, H-6a), 4.55 (d, 1H, J6b,5 
2.1 Hz, H-6b), 3.9-3.8 (m, 1H, H-5), 3.66 (s, 3H, OCH3), 3.55-3.4 (m, 8H, 2 x OCH3, H-3, H-
4), 3.25 (dd, 1H, J2,3 9.1 Hz, H-2), 2.96 (bs, 1H, 4-OH); 13C NMR (90 MHz, CDCl3): δ (ppm) 
166.8 (OCOPh), 133.2 (m aromatic), 129.7, 128.4 (o and p aromatic), 97.4 (C-1), 82.6, 81.7 
(C-2, C-3), 70.1, 69.5 (C-4, C-5), 63.7 (C-6), 61.3, 58.6 (2 x OCH3), 55.2 (anomeric OCH3); 
Anal. Calcd. for C16H22O7 (326.34): C 58.89, H 6.79. Found: C 58.63, H 6.89. 
 
4.1.11. Methyl 2,3-di-O-methyl--D-glucopyranoside (12) 
 
To a solution of 9 (67 mg, 0.13 mmol) in dry CH2Cl2 (1 mL) at 0 °C was added 
BF3OEt2 (2 µL) and the mixture was stirred for 20 min. TLC (1:1 hexane-EtOAc) showed 
complete conversion of the starting material (Rf 0.82) into the title compound (Rf 0.22). Then 
1 drop of TEA was added and the solution was evaporated. After column chromatography 
(1:1 hexane-EtOAc) compound 1210 (24 mg, 86%) was isolated as a syrup: []D +170 (c 0.98, 
CHCl3), lit.10b +174; 1H- and 13C-NMR datas were in very good agreement with those 
reported in the literature.10b 
 
4.1.12. Methyl 6-O-(9’,10’-dihydro-9’-anthracenyl)methyl-2,3-di-O-methyl--D-
glucopyranoside (13) and 1,5-anhydro-6-O-(9’,10’-dihydro-9’-anthracenyl)methyl-2,3-
di-O-methyl-D-glucitol (14) 
 
To a solution of 6 (250 mg, 0.60 mmol) in dry CH2Cl2 (2 mL) was added Et3SiH (484 
µL, 5 equiv) at 0 °C, then BF3OEt2 (154 µL, 2 equiv) was also added and the mixture was 
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stirred overnight at rt. After TLC (7:3 hexane-acetone) indicated the formation of two 
products, the reaction mixture was diluted with CH2Cl2, washed with water, satd NaHCO3, 
then again with water, dried (MgSO4) and concentrated. After column chromatography 
(8:27:3 hexane-acetone) compound 13 (Rf 0.42, 49 mg, 20%), compound 14 (Rf 0.46, 52 
mg) and unreacted 6 (34 mg, 14%) were isolated as syrups. Compound 13: []D +62 (c 0.14, 
CHCl3); 1H NMR (500 MHz, CDCl3) δ (ppm) 7.36-7.19 (m, 8H, aromatic), 4.78 (d, 1H, J1,2 
3.6 Hz, H-1), 4.22 (t, 1H, J 7.3 Hz, H-9’), 4.13 (d, 1H, J 18.5 Hz, H-10’a), 3.88 (d, 1H, J 18.5 
Hz, H-10’b), 3.65-3.56 (m, 6H), 3.61 (s, 3H, OCH3), 3.48 (s, 3H, OCH3), 3.47-3.36 (m, 2H), 
3.35 (s, 3H, OCH3), 3.15 (dd, 1H, J 9.1 Hz, H-1); 13C NMR (125 MHz, CDCl3): δ (ppm) 
137.1, 137.0, 136.1, 128.8, 128.7, 127.7, 127.7, 126.5, 126.1, 126.0 (aromatic), 97.3 (C-1), 
82.6, 81.6 (C-2, C-3) 75.6 (C-11’), 71.0, 69.8 (C-4, C-5), 70.9 (C-6), 61.0, 58.5 (2 x OCH3), 
55.0 (OCH3 anomeric), 47.5 (C-9’), 35.1 (C-10’). MALDI-TOF MS m/z calcd. for C24H30O6 : 
414.20. Found: 437.42 [M+Na]+. Anal. Calcd. for C24H30O6 (414.49): C 69.54, H 7.30. 
Found: C 69.43, H 7.38. 
Compound 14 containing impurities was purified and characterized after acetylation. 
 
4.1.13. 4-O-acetyl-1,5-anhydro-6-O-(9’,10’-dihydro-9’-anthracenyl)methyl-2,3-di-O-
methyl-D-glucitol (15) 
 
The isolated 14 (52 mg) containing impurities was acetylated with Ac2O (0.5 mL) in 
pyridine (1 mL). The mixture was diluted with CH2Cl2, washed twice with water, dried and 
concentrated. After column cromatography (7:3 hexane-acetone) compound 15 (37 mg, 14% 
for two steps) was isolated as a syrup: []D +16 (c 0.14, CHCl3); 1H NMR (500 MHz, 
CDCl3): δ (ppm) 7.31-7.19 (m, 8H, aromatic), 4.66 (t, 1H, J 9.3 Hz), 4.18 (t, 1H, J 7.1 Hz, H-
9’), 4.12 (d, 1H, J 18.0 Hz, H-10’a), 4.02 (dd, 1H, J 11.3 Hz, J 5.3 Hz), 3.87 (d, 1H, J 18.5 
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Hz, H-10’b), 3.63 (dd, 1H, J 8.2 Hz, J 6.6 Hz), 3.56-3.45 (m, 7H, incl. 2 x OCH3), 3.40-3.20 
(m, 4H), 3.17 (t, 1H, J 9.0 Hz), 3.04 (t, 1H, J 11.0 Hz), 2.0 (s, 3H, OCOCH3); 13C NMR (125 
MHz, CDCl3): δ (ppm) 169.8 (CO), 137.2, 137.0, 136.3, 136.2, 129.0, 128.8, 128.7, 127.6, 
127.6, 126.5, 126.4, 126.2, 126.1 (aromatic), 84.9, 79.3, 78.0 (C-2, C-3, C-4), 75.8 (C-11’), 
71.0 (C-6), 70.7 (C-5), 67.5 (C-1), 60.52 (OCH3), 58.8 (OCH3), 47.6 (C-9’), 35.2 (C-10’), 
20.9 (OCOCH3). MALDI-TOF MS m/z calcd. for C25H30O6 : 426.20. Found: 449.39 
[M+Na]+. Anal. Calcd. for C25H30O6: C 70.40, H 7.09. Found: C 70.29, H 7.17. 
 
4.1.14. Methyl 2,3-O-(9’-anthracenyl)methylene--L-rhamnopyranoside (17exo, 17endo) 
and methyl-4-O-acetyl-2,3-O-(9’-anthracenyl)methylene--L-rhamnopyranoside (18exo, 
18endo) 
 
Crystalline methyl -L-rhamnopyranoside 1625 (5.35 g, 30.2 mmol) was converted into 
the title compound according to the method described for 2. The crude product was 
crystallized from EtOAc-hexane to give the 17exo isomer (4.80 g, 43%). The mother liquor 
containing the exo and endo isomers could not be separated by crystallization therefore it was 
acetylated with Ac2O (2 mL) in pyridine (3 mL). TLC (8:4 hexane-EtOAc) showed two new 
spots (Rf 0.41 acetylated endo and Rf 0.49 acetylated exo isomers). The mixture was diluted 
with CH2Cl2, washed twice with water, dried and concentrated. The isomers were separated 
with column chromatography on silica gel (8:2 hexane-EtOAc) to yield 1.276 g of 18endo 
and 410 mg of 18exo isomers. Deacetylation of compound 18endo and 18exo with cat. 
amount of NaOMe in MeOH (3 mL) followed by neutralization with Amberlite IR-120 H+ 
resin, evaporated and 17endo (1.03 g, 90%) and 17exo (324 mg, 88%) were yielded, 
respectively. In summary 5.124 g 17exo (46%) and 1.03 g 17endo (9%) were isolated.  
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Compound 17exo: mp 201-202 °C; []D +26 (c 0.22, CHCl3); 1H NMR (500 MHz, 
CDCl3): δ (ppm) 8.50 (d, 2H, J 9.0 Hz, H-1’, H-8’), 8.46 (s, 1H, H-10’), 7.97 (d, 2H, J 8.4 
Hz, H-4’, H-5’), 7.50-7.40 (m, 5H, H-2’, H-3’, H-6’, H-7’, H acetalic), 4.99 (s, 1H, H-1), 4.76 
(t, 1H, J 6.5 Hz, H-3), 4.56 (d, 1H, J2,3 6.2 Hz, H-2), 3.85-3.75 (m, 2H, H-4, H-5), 3.44 (s, 1H, 
OH), 3.39 (s, 3H, OCH3), 1.43 (d, 3H, J6,5 6 Hz, CH3-6); 13C NMR (125 MHz, CDCl3): δ 
(ppm) 131.2, 130.5, 130.3, 129.0, 126.2, 124.8, 124.6, 123.7 (aromatic), 100.3 (C acetalic), 
98.8 (C-1), 80.3 (C-3), 76.0 (C-2), 70.4 (C-4), 65.1 (C-5), 54.7 (OCH3), 17.4 (C-6). MALDI-
TOF MS m/z calcd. for C22H22O5: 366.15. Found: 367.37 [M+H]+ and 389.34 [M+Na]+ and 
397.24 [M+K]+. Anal. Calcd. for C22H22O5: C 72.12, H 6.05. Found: C 72.01, H 6.15. 
Compound 17endo: mp 182-184 °C; []D -32 (c 0.13; CHCl3); 1H NMR (500 MHz, 
CDCl3): δ (ppm) 8.70 (d, 2H, J 9.5 Hz, H-1’, H-8’), 8.45 (s, 1H, H-10’), 7.94 (d, 2H, J 8.5 
Hz, H-4’, H-5’), 7.50-7.40 (m, 4H, H-2’, H-3’, H-6’, H-7’), 7.08 (s, 1H, acetalic), 5.08 (s, 1H, 
H-1), 4.36 (bt, 1H, J 6.5 Hz, J 7.0 Hz, H-3), 4.30 (d, 1H, J2,3 7.5 Hz, H-2), 3.78-3.74 (m, 1H, 
H-5), 3.62 (dd, 1H, J4,5 8.5 Hz, J4,3 6.0 Hz, H-4), 3.41 (s, 3H, OCH3), 3.01 (bs, 1H, OH), 1.22 
(d, 3H, J6,5 6.5 Hz, CH3-6); 13C NMR (125 MHz, CDCl3): δ (ppm) 131.4, 130.5, 129.1, 126.4, 
124.8, 124.6, 124.0 (aromatic), 102.2 (C acetalic), 98.4 (C-1), 78.0, 77.4 (C-2, C-3), 73.5 (C-
4), 66.3 (C-5), 55.0 (OCH3), 18.0 (C-6). Anal. Calcd. for C22H22O5 (366.41): C 72.12, H 6.05. 
Found: C 72.26, H 5.90. 
Compound 18exo (4-O-acetyl): mp 213-214 °C; []D +90 (c 0.14; CHCl3); 1H NMR 
(360 MHz, CDCl3): δ (ppm) 8.54 (d, 2H, J 9.0 Hz, H-1’, H-8’), 8.48 (s, 1H, H-10’), 7.98 (d, 
2H, J 8.0 Hz, H-4’, H-5’), 7.58 (s, 1H, H acetalic), 7.55-7.40 (m, 4H, H-2’, H-3’, H-6’, H-7’), 
5.35 (dd, 1H, J4,5 9.2 Hz, H-4), 5.06 (s, 1H, H-1), 4.84 (dd, 1H, J3,4 7.7 Hz, H-3), 4.62 (d, 1H, 
J2,3 5.8 Hz, H-2), 3.95-3.88 (m, 1H, H-5), 3.43 (s, 3H, OCH3), 2.11 (s, 3H, OCOCH3), 1.34 
(d, 3H, J6,5 6.3 Hz, CH3-6); 13C NMR (90 MHz, CDCl3): δ (ppm) 170.2 (CO), 131.4, 130.7, 
130.6, 129.1, 126.5, 124.8, 123.9 (aromatic), 100.8 (C acetalic), 98.8 (C-1), 77.9, 76.3, 70.2 
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(C-2, C-3, C-4), 63.2 (C-5), 55.1 (OCH3), 20.9 (COCH3), 17.2 (C-6); Anal. Calcd. for 
C24H24O6 (408.44): C 70.57, H 5.92. Found: C 70.60, H 5.99. 
Compound 18endo (4-O-acetyl): mp 194-196 °C; []D +43 (c 0.16; CHCl3); 1H NMR 
(500 MHz, CDCl3): δ (ppm) 8.69 (d, 2H, J 9 Hz, H-1’, H-8’), 8.49 (s, 1H, H-10’), 7.98 (d, 
2H, J 8.3 Hz, H-4’, H-5’), 7.55-7.40 (m, 4H, H-2’, H-3’, H-6’, H-7’), 7.12 (s, 1H, H acetalic), 
5.20 (dd, 1H, J4,5 9.5 Hz, H-4), 5.14 (s, 1H, H-1), 4.57 (dd, 1H, J3,4 5.7 Hz, H-3), 4.43 (d, 1H, 
J2,3 7.6 Hz, H-2), 3.95-3.88 (m, 1H, H-5), 3.45 (s, 3H, OCH3), 2.02 (s, 3H, OCOCH3), 1.34 
(d, 3H, J6,5 6.4 Hz, CH3-6); 13C NMR (125 MHz, CDCl3): δ (ppm) 169.6 (CO), 131.4, 130.8, 
130.7, 129.1, 126.4, 124.8, 124.4, 123.4 (aromatic), 101.8 (C acetalic), 98.8 (C-1), 77.4, 75.8, 
74.5 (C-2, C-3, C-4), 63.9 (C-5), 55.1 (OCH3), 20.9 (COCH3), 18.1 (C-6), Anal. Calcd. for 
C24H24O6 (408.44): C 70.57, H 5.92. Found: C 70.46, H 6.06. 
 
4.1.15. Methyl 3-O-(9’-anthracenyl)methyl--L-rhamnopyranoside (19) and methyl 2-O-
(9’-anthracenyl)methyl--L-rhamnopyranoside (20) 
 
Prepared from 17exo (100 mg, 0.27 mmol) according to the same procedure as 
described for 4. After column chromatography (7:3 hexane-acetone) compound 19 (20 mg, 
20%) and compound 20 (36 mg, 32%) were isolated as syrups.  
Compound 19: []D +22 (c 0.06, CHCl3); 1H NMR (500 MHz, OCH3): δ (ppm) 8.50 (s, 
1H, H-10’), 8.36 (d, 2H, J 8.9 Hz, H-1’, H-8’), 8.03 (d, 2H, J 8.5 Hz, H-4’, H-5’), 7.60-7.40 
(m, 4H, H-2’, H-3’, H-6’, H-7’), 5.73 (d, 1H, J 11.3 Hz, Ar-CH2), 5.53 (d, 1H, J 11.2 Hz, Ar-
CH2), 4.76 (s, 1H, H-1), 4.29 (d, 1H, J2,1 1.5 Hz, H-2), 3.86 (dd, 1H, J3,4 9.2 Hz, J 3.25 Hz, H-
3), 3.69-3.64 (m, 1H, H-5), 3.51 (t, 1H, J4,5 9.3 Hz, H-4), 3.38 (s, 3H, OCH3), 1.29 (d, 3H, J6,5 
6.25 Hz, CH3-6); 13C NMR (125 MHz, CDCl3): δ (ppm) 131.4, 130.9, 129.3, 128.9, 127.8, 
126.8, 125.1, 123.6 (aromatic), 100.5 (C-1), 80.0, 71.6, 68.0, 67.5 (C-2, C-3, C-4, C-5), 63.6 
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(ArCH2), 54.9 (OCH3), 17.6 (C-6); Anal. Calcd. for C22H24O5 (368.42): C 71.72, H 6.57. 
Found: C 71.40, H 6.88. 
Compound 20: []D +34 (c 0.12, CHCl3); 1H NMR (500 MHz, CDCl3): δ (ppm) 8.32 (s, 
1H, H-10’), 8.29 (d, 2H, J 9.0 Hz, H-1’, H-8’), 7.88 (d, 2H, J 8.4 Hz, H-4’, H-5’), 7.55-7.37 
(m, 4H, H-2’, H-3’, H-6’, H-7’), 5.60 (d, 1H, J 11.3 Hz, Ar-CH2), 5.37 (d, 1H, J 11.2 Hz, Ar-
CH2), 5.00 (s, 1H, H-1), 3.81 (dd, 1H, J2,3 3.7 Hz, J2,1 1.1 Hz, H-2), 3.62 (dd, 1H, J3,4 9.4 Hz, 
H-3), 3.58-3.50 (m, 1H, H-5), 3.36 (s, 3H, OCH3), 3.19 (t, 1H, J4,5 9.4 Hz, H-4), 1.24 (d, 3H, 
J6,5 6.2 Hz, CH3-6); 13C NMR (125 MHz, CDCl3): δ (ppm) 131.3, 130.8, 129.0, 128.7, 127.8, 
126.5, 125.0, 123.9 (aromatic), 97.8 (C-1), 78.0, 73.6, 71.4, 67.7 (C-2, C-3, C-4, C-5), 64.4 
(ArCH2), 54.8 (OCH3), 17.5 (C-6); Anal. Calcd. for C22H24O5 (368.42): C 71.72, H 6.57. 
Found: C 71.56, H 6.65.  
Starting from 17endo (150 mg, 0.41 mmol) the previous ring-opening method gave only 20 
(88 mg, 58%). 
 
4.1.16. Methyl 2,3-O-(9’-anthracenyl)methylene-4-O-benzyl--L-rhamnopyranoside 
(21exo) 
 
To a solution of 17exo (220 mg, 0.6 mmol) in dry DMF (3 mL) was added NaH (35 mg, 
2 equiv.) at 0 °C and stirred for 30 min. Benzyl bromide (79 µL, 1.2 equiv.) was added to the 
mixture and stirred for another 30 min. After complete conversion 2-3 mL of EtOAc and 1-5 
drops of water were added, the mixture was diluted with EtOAc, washed 3 times with water, 
dried and concentrated. After column chromatography (8:2 hexane-EtOAc, Rf 0.48) 
compound 21exo (253 mg, 92%) was isolated as an amorf material. Crystallization of 22exo 
from hexane-EtOAc afforded pale yellow crystals: mp 142 °C; []D +47.2 (c 0.04, CHCl3);1H 
NMR (360 MHz, CDCl3): δ (ppm) 8.50 (s, 1H, aromatic), 8.46 (d, 2H, J 8.9 Hz, aromatic), 
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8.00 (d, 2H, J 8.2 Hz, aromatic), 7.56-7.41 (m, 4H, aromatic), 7.37 (s, 1H, H-acetalic), 7.35-
7.25 (m, 5H), 5.03-4.97 (m, 2H), 4.95 (d, 1H, J 11.9 Hz, PhCHH), 4.77 (d, 1H, J 11.8 Hz, 
PhCHH), 4.62 (d, 1H, J 6.3 Hz), 3.94-3.84 (m, 1H, H-5), 3.58 (dd, 1H, J 9.6 Hz, J 6.9 Hz), 
3.39 (s, 3H, OCH3), 1.43 (d, 3H, J 6.2 Hz, CH3-6); 13C NMR (90 MHz, CDCl3): δ (ppm) 
137.8, 131.5, 130.7, 130.6, 129.2, 128.4, 128.3, 127.7, 126.4, 125.0, 124.8, 123.9 (aromatic), 
100.3 (C acetalic), 99.0 (C-1), 80.5, 76.4, 76.2, 63.6 (C-2, C-3, C-4, C-5), 72.3 (PhCH2), 18.1 
(C-6). MALDI-TOF MS m/z calcd. for C29H28O5: 456.53. Found: 456.51 [M]+ 479.50 
[M+Na]+. Anal. Calcd. for C29H28O5: C 76.30, H 6.18. Found: C 76.46, H 6.09. 
 
4.1.17. Methyl 3-O-(9’-anthracenyl)methyl-4-O-benzyl--L-rhamnopyranoside (22) 
 
Prepared from 21exo (133 mg, 0.3 mmol) according to the same method as described 
for the synthesis of 4. Column chromatography (75:25 hexane-EtOAc, Rf 0.21) of the mixture 
gave compound 22 (86 mg, 65%) as a syrup: []D -32.8 (c 0.12, CHCl3);1H NMR (360 MHz, 
CDCl3): δ (ppm) 8.47 (s, 1H, aromatic), 8.33 (d, 2H, J 8.5 Hz, aromatic), 8.00 (d, 2H, J 8.0 
Hz, aromatic), 7.50-7.10 (m, 9H, aromatic), 5.71 (d, 1H, J 10.8 Hz, anthr-CHH), 5.52 (d, 1H, 
J 10.8 Hz, anthr-CHH), 4.77 (d, 1H, J 11.2 Hz, PhCHH), 4.76 (s, 1H, H-1), 4.48 (d, 1H, J 
11.2 Hz, PhCHH), 4.32 (s, 1H), 4.12 (dd, 1H, J 9.1 Hz J 3.2 Hz), 3.83-3.74 (m, 1H, C-5), 
3.43-3.35 (m, 5H, OCH3), 1.31 (d, 3H, J 6.2 Hz, CH3-6); 13C NMR (90 MHz, CDCl3): δ 
(ppm) 138.5, 131.4, 130.8, 129.1, 128.7, 128.2, 127.5, 126.6, 125.0, 123.8 (aromatic), 100.1 
(C-1), 80.59, 79.60 (C-3, C-4), 75.2 (PhCH2), 68.5, 67.3 (C-2, C-5), 63.9 (anthr-CH2), 54.81 
(OCH3), 17.9 (C-6). MALDI-TOF MS m/z calcd. for C29H30O5: 458.55. Found: 481.52 
[M+Na]+. Anal. Calcd. for C29H30O5: C 75.96, H 6.59. Found: C 76.05, H 6.51. 
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4.1.18. Methyl 2,3-O-(9’,10’-dihydro-9’-anthracenyl)methylene--L-rhamnopyranoside 
(23) 
 
Prepared from 17exo (2.14 g, 5.84 mmol) according to the same method as described 
for the synthesis of 6. After 8 h the reaction was completed according to TLC (6:4 hexane-
aceton, Rf 0.55). After column chromatography compound 23exo (2.06 g, 95%) was isolated 
as a syrup: []D -22 (c 0.17, CHCl3); 1H NMR (360 MHz, CDCl3): δ (ppm) 7.35-7.10 (m, 8H, 
aromatic), 5.44 (d, 1H, J 2.8 Hz, H-acetalic), 4.67 (s, 1H, H-1), 4.24 (d, 1H, J 18.3 Hz, Ar-
CH2), 4.16 (s, 1H), 3.89 (dd, 1H, J 7.4 Hz, J 5.2 Hz), 3.81 (d, 1H, J 18.4 Hz, Ar-CH2), 3.50-
3.40 (m, 1H, H-5), 3.25 (s, 3H, OCH3), 3.20-3.10 (m, 2H), 2.15 (bs, 1H, OH), 1.19 (d, 3H, J6,5 
6.2 Hz, CH3-6); 13C NMR (90 MHz, CDCl3): δ (ppm) 137.6, 137.6, 134.1, 134.0, 129.6, 
129.2, 127.7, 127.6, 126.9, 126.0, 125.8 (aromatic), 107.4 (C-acetalic), 97.7 (C-1), 79.0, 75.5, 
71.4, (C-2, C-3, C-4), 64.8 (C-5), 54.7 (OCH3), 51.7 (C-9’), 35.9 (C-10’), 17.2 (C-6). 
MALDI-TOF MS m/z calcd. for C22H24O5: 368.16. Found: 391.41 [M+Na]+. Anal. Calcd. for 
C22H24O5: C 71.72, H 6.57. Found: C 71.62, H 6.67. 
 
Supplementary data 
Complete crystallographic data for the structural analysis of 4,6-O-(9’,10’-dihydro-9’-
anthracenyl)methylene-2,3-di-O-methyl--D-glucopyranoside (6) have been deposited with 
the Cambridge Crystallographic Data Centre, CCDC no. 736551. Copies of this information 
may be obtained free of charge from the Director, Cambridge Crystallographic Data Centre, 
12 Union Road, Cambridge, CB2 1EZ, UK. (fax: +44-1223-336033, e-mail: 
deposit@ccdc.cam.ac.uk or via: www.ccdc.cam.ac.uk). 
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